19 December 2019

Is Your IND, NDA, or BLA on the OND's List?

Written by Liz Bloss



The FDA’s restructuring of its Office of New Drugs (OND) is well underway with Phase II having kicked off earlier this month and Phase III slated to begin in early December. Wondering how your IND, NDA, or BLA has been affected? See the latest from the FDA here.  Included on the page is a spreadsheet listing affected applications. (Go directly to the Excel file.)

Questions? Concerns?

Reach out to us at The Bracken Group for more on the OND reorg and all things concerning regulatory affairs and the life sciences.


New call-to-action


6 Ways to Use Clinical Trial Condition Data for Life Science Sales

Life science sales teams know that data is essential to successful sales, but many of us could..

How Data Builds Trust in the Unique World of Life Science Sales

“Establishing trust is better than any sales technique.” – Mike Puglia   Many sales professionals..